Recent News
On June 20, 2026 the company drew market attention after a report noted its shares effectively stopped trading on Nasdaq and highlighted a shift in investor focus toward Syros’s underlying business model and clinical pipeline amid minimal fresh corporate announcements.
Technical Analysis
ADX / DI+ / DI-: ADX at 24.44 signals an emerging trend strength. DIpositive shows a dip & reversal, indicating renewed bullish directional pressure; DInegative shows a peak & reversal, which also reads bullish as selling momentum has begun to wane. Together these directional indicators imply a developing bullish tilt against a still-fragile trend backbone.
MACD: MACD at -2.45 with the MACD trend decreasing and the signal line at -0.66 denotes continuing bearish momentum; the negative, declining MACD constrains near-term upside despite directional indicator shifts.
MRO: MRO at 9.34 sits positive, indicating price above target with mild downward pressure expected; the strength reads weak, so downside potential tied to MRO looks limited rather than severe.
RSI: RSI at 51.09 with a decreasing trend reflects neutral-to-slightly bearish momentum; neither overbought nor oversold conditions should drive a decisive move alone.
Price vs Averages & Bands: Last close $90.79 sits below the 20-day average ($96.19) and 50-day average ($98.13) while remaining above the 200-day average ($62.32), a setup that pairs shorter-term pressure with longer-term outperformance. Price sits inside the Bollinger band inner range (lower $86.20 – upper $106.18), nearer the lower band, which supports limited mean-reversion potential if selling cools.
Ichimoku & EMAs: Tenkan/Kijun at $97.09 and Senkou A $96.05 place price beneath the short-term pivot levels, with Senkou B at $84.88 below the market — a configuration consistent with consolidation above longer-term cloud support but below short-term resistance. The 12-day EMA trend decreasing adds to short-term pressure.
Volatility & Volume: 42-day beta 1.30 and 52-week beta 1.84 indicate above-market sensitivity. Recent volume (1,248,120) sits below the 10-day average (1,395,418) and roughly in line with the 50/200-day averages, suggesting reduced participation during the latest price consolidation.
Fundamental Analysis
Profitability & Income: Trailing operating loss (EBIT/EBITDA) equals -$81,639,000; net loss for the period -$36,200,000. EPS actual -$0.36 beat the estimate of -$0.75 by $0.39, a positive EPS surprise of 52.0%.
Liquidity & Cash: Cash and short-term investments total $1,145,346,000 and cash alone $162,007,000. Current ratio stands at 18.53, a QoQ increase of 6.57% and a YoY increase of 185.64%, reflecting a substantial liquidity buffer relative to near-term liabilities.
Cash Flow & Free Cash: Operating and free cash flow remain negative; free cash flow -$69,877,000 with a free cash flow yield of -0.93%. Free cash growth shows +21.80% YoY but declined QoQ by 24.06%, indicating improvement year-over-year yet short-term cash conversion weakness.
Returns: Return on assets -3.74% improved relative to the industry peer mean of -4.36% (industry peer mean) and return on equity -3.79% sits above the industry peer mean of -10.42% (industry peer mean); both metrics stay negative but register better outcomes than the industry peer mean reported.
Valuation Multiples: Price-to-book at 7.88 sits slightly below the industry peer mean of 8.32 and slightly above the industry peer median of 6.33. Price-to-earnings reads negative (-237.41) and forward P/E remains negative, reflecting lack of positive earnings. PEG at 4.62 and forward PEG 1.70 present stretched forward multiples, although PEG ratio YoY rose roughly 154.54% per the supplied change metric.
Balance Sheet & Scale: Total assets $1,173,003,000, total equity $954,716,000, and invested capital $954,716,000 produce an asset-to-equity ratio of 1.23 and a cash ratio of 18.09, underscoring a conservative liability base (total liabilities $71,862,000) and a strong short-term coverage profile.
R&D & Operating Spend: Research and development expense $65,503,000 drives the operating loss and reflects ongoing pipeline investment consistent with a clinical-stage biotech profile.
Valuation Note: The current valuation as determined by WMDST rates the stock under-valued given the firm’s sizeable cash and short-term investments, materially light liabilities, and pipeline assets; that view balances near-term negative cash flow against a capital base that supports continued development.
MOST-RECENT QUARTERLY REPORT
| REPORT PERIOD ENDING: | 2026-06-30 |
| REPORT DATE: | 2026-08-04 |
| NEXT REPORT DATE: | 2026-11-03 |
| CASH FLOW | Begin Period Cash Flow | $ 97.2 M |
| Operating Cash Flow | — | |
| Capital Expenditures | — | |
| Change In Working Capital | $ -9.01 M | |
| Dividends Paid | — | |
| Cash Flow Delta | $ 64.8 M | |
| End Period Cash Flow | $ 162.0 M | |
| INCOME STATEMENT | REVENUE | |
| Total Revenue | — | |
| Forward Revenue | — | |
| COSTS | ||
| Cost Of Revenue | — | |
| Depreciation | — | |
| Depreciation and Amortization | — | |
| Research and Development | $ 65.5 M | |
| Total Operating Expenses | $ 81.6 M | |
| PROFITABILITY | ||
| Gross Profit | — | |
| EBITDA | $ -81.64 M | |
| EBIT | $ -81.64 M | |
| Operating Income | $ -81.64 M | |
| Interest Income | $ 10.1 M | |
| Interest Expense | — | |
| Net Interest Income | $ 10.1 M | |
| Income Before Tax | $ -36.20 M | |
| Tax Provision | — | |
| Tax Rate | — | |
| Net Income | $ -36.20 M | |
| Net Income From Continuing Operations | $ -36.20 M | |
| EARNINGS | ||
| EPS Estimate | $ -0.75 | |
| EPS Actual | $ -0.36 | |
| EPS Difference | $ 0.39 | |
| EPS Surprise | 52.0 % | |
| Forward EPS | $ -0.88 | |
| BALANCE SHEET | ASSETS | |
| Total Assets | $ 1.2 B | |
| Intangible Assets | — | |
| Net Tangible Assets | $ 1.1 B | |
| Total Current Assets | $ 1.2 B | |
| Cash and Short-Term Investments | $ 1.1 B | |
| Cash | $ 162.0 M | |
| Net Receivables | — | |
| Inventory | — | |
| Long-Term Investments | — | |
| LIABILITIES | ||
| Accounts Payable | $ 5.7 M | |
| Short-Term Debt | — | |
| Total Current Liabilities | $ 63.3 M | |
| Net Debt | — | |
| Total Debt | — | |
| Total Liabilities | $ 71.9 M | |
| EQUITY | ||
| Total Equity | $ 954.7 M | |
| Retained Earnings | $ -1.23 B | |
| VALUATION & PER-SHARE METRICS | EQUITY & PER-SHARE METRICS | |
| Book Value Per-Share | $ 10.84 | |
| Shares Outstanding | 88.064 M | |
| Revenue Per-Share | — | |
| VALUATION | Market Capitalization | $ 7.5 B |
| Enterprise Value | — | |
| Enterprise Multiple | — | |
| Enterprise Multiple QoQ | — | |
| Enterprise Multiple YoY | — | |
| Enterprise Multiple IPRWA | — | |
| EV/R | — | |
| CAPITAL STRUCTURE | ||
| Asset To Equity | 1.229 | |
| Asset To Liability | 16.323 | |
| Debt To Capital | — | |
| Debt To Assets | — | |
| Debt To Assets QoQ | — | |
| Debt To Assets YoY | — | |
| Debt To Assets IPRWA | — | |
| Debt To Equity | — | |
| Debt To Equity QoQ | — | |
| Debt To Equity YoY | — | |
| Debt To Equity IPRWA | — | |
| PRICE-BASED VALUATION | ||
| Price To Book (P/B) | 7.884 | |
| Price To Book QoQ | -1.991 % | |
| Price To Book YoY | 138.459 % | |
| Price To Book IPRWA | high: 18.326 mean: 8.317 SYRE: 7.884 median: 6.334 low: -9.25 |
|
| Price To Earnings (P/E) | -237.415 | |
| Price To Earnings QoQ | 234.363 % | |
| Price To Earnings YoY | 612.957 % | |
| Price To Earnings IPRWA | high: 116.461 median: 38.38 mean: 15.64 low: -149.856 SYRE: -237.415 |
|
| PE/G Ratio | 4.623 | |
| Price To Sales (P/S) | — | |
| Price To Sales QoQ | — | |
| Price To Sales YoY | — | |
| Price To Sales IPRWA | — | |
| FORWARD MULTIPLES | ||
| Forward P/E | -87.538 | |
| Forward PE/G | 1.705 | |
| Forward P/S | — | |
| EFFICIENCY | OPERATIONAL | |
| Operating Leverage | — | |
| ASSET & SALES | ||
| Asset Turnover Ratio | — | |
| Asset Turnover Ratio QoQ | — | |
| Asset Turnover Ratio YoY | — | |
| Asset Turnover Ratio IPRWA | — | |
| Receivables Turnover | — | |
| Receivables Turnover Ratio QoQ | — | |
| Receivables Turnover Ratio YoY | — | |
| Receivables Turnover Ratio IPRWA | — | |
| Inventory Turnover | — | |
| Inventory Turnover Ratio QoQ | — | |
| Inventory Turnover Ratio YoY | — | |
| Inventory Turnover Ratio IPRWA | — | |
| Days Sales Outstanding (DSO) | — | |
| CASH CYCLE | ||
| Cash Conversion Cycle Days (CCC) | — | |
| Cash Conversion Cycle Days QoQ | — | |
| Cash Conversion Cycle Days YoY | — | |
| Cash Conversion Cycle Days IPRWA | high: 564.313 median: 244.94 mean: 168.335 SYRE: 0 low: -329.732 |
|
| CAPITAL DEPLOYMENT | ||
| Cash Conversion Ratio | — | |
| CapEx To Revenue | — | |
| CapEx To Depreciation | — | |
| CAPITAL, LIQUIDITY & COVERAGE | CAPITAL STRUCTURE | |
| Total Capital | $ 1.1 B | |
| Net Invested Capital | $ 954.7 M | |
| Invested Capital | $ 954.7 M | |
| Net Tangible Assets | $ 1.1 B | |
| Net Working Capital | $ 1.1 B | |
| LIQUIDITY | ||
| Cash Ratio | 18.093 | |
| Current Ratio | 18.53 | |
| Current Ratio QoQ | 106.567 % | |
| Current Ratio YoY | 185.637 % | |
| Current Ratio IPRWA | high: 31.351 SYRE: 18.53 mean: 5.07 median: 3.185 low: 0.048 |
|
| Quick Ratio | — | |
| Quick Ratio QoQ | — | |
| Quick Ratio YoY | — | |
| Quick Ratio IPRWA | — | |
| COVERAGE & LEVERAGE | ||
| Debt To EBITDA | — | |
| Cost Of Debt | — | |
| Interest Coverage Ratio | — | |
| Interest Coverage Ratio QoQ | — | |
| Interest Coverage Ratio YoY | — | |
| Interest Coverage Ratio IPRWA | — | |
| Operating Cash Flow Ratio | 0.0 | |
| TIMING / LIQUIDITY | ||
| Days Payables Outstanding (DPO) | — | |
| DIVIDENDS | ||
| Dividend Coverage Ratio | — | |
| Dividend Payout Ratio | — | |
| Dividend Rate | — | |
| Dividend Yield | — | |
| PERFORMANCE | GROWTH | |
| Asset Growth Rate | 53.544 % | |
| Revenue Growth | — | |
| Revenue Growth QoQ | — | |
| Revenue Growth YoY | — | |
| Revenue Growth IPRWA | — | |
| Earnings Growth | -51.351 % | |
| Earnings Growth QoQ | — | |
| Earnings Growth YoY | 180.101 % | |
| Earnings Growth IPRWA | high: 175.0 % mean: 12.56 % median: 12.5 % SYRE: -51.351 % low: -155.294 % |
|
| MARGINS | ||
| Gross Margin | — | |
| Gross Margin QoQ | — | |
| Gross Margin YoY | — | |
| Gross Margin IPRWA | — | |
| EBIT Margin | — | |
| EBIT Margin QoQ | — | |
| EBIT Margin YoY | — | |
| EBIT Margin IPRWA | — | |
| Return On Sales (ROS) | — | |
| Return On Sales QoQ | — | |
| Return On Sales YoY | — | |
| Return On Sales IPRWA | — | |
| CASH FLOW | ||
| Free Cash Flow (FCF) | $ -69.88 M | |
| Free Cash Flow Yield | -0.928 % | |
| Free Cash Flow Yield QoQ | -32.996 % | |
| Free Cash Flow Yield YoY | -80.234 % | |
| Free Cash Flow Yield IPRWA | high: 13.067 % median: 0.852 % mean: 0.412 % SYRE: -0.928 % low: -37.582 % |
|
| Free Cash Growth | 21.796 % | |
| Free Cash Growth QoQ | -24.056 % | |
| Free Cash Growth YoY | 60.442 % | |
| Free Cash Growth IPRWA | high: 175.34 % SYRE: 21.796 % mean: 18.379 % median: 1.424 % low: -209.632 % |
|
| Free Cash To Net Income | 1.93 | |
| Cash Flow Margin | — | |
| Cash Flow To Earnings | 0.0 | |
| VALUE & RETURNS | ||
| Economic Value Added | — | |
| Return On Assets (ROA) | -3.738 % | |
| Return On Assets QoQ | -58.244 % | |
| Return On Assets YoY | -43.569 % | |
| Return On Assets IPRWA | high: 34.781 % median: 0.09 % SYRE: -3.738 % mean: -4.361 % low: -58.264 % |
|
| Return On Capital Employed (ROCE) | -7.357 % | |
| Return On Equity (ROE) | -0.038 | |
| Return On Equity QoQ | -71.699 % | |
| Return On Equity YoY | -69.022 % | |
| Return On Equity IPRWA | high: 0.542 median: 0.005 SYRE: -0.038 mean: -0.104 low: -0.887 |
|
| DuPont ROE | — | |
| Return On Invested Capital (ROIC) | — | |
| Return On Invested Capital QoQ | — | |
| Return On Invested Capital YoY | — | |
| Return On Invested Capital IPRWA | — | |